Hypofractionated Radiotherapy for Soft Tissue Sarcomas

Status Active, not recruiting

Clinical Trial Summary

One of the main challenges in treating sarcomas with radiation is the toxicity to normal structures around the sarcoma. Early reports suggest Hypofractionated Radiotherapy will be safe and effective for treatment of soft tissue sarcomas. However, given the rarity of this disease, the diversity of histological sub-types, and the variety of locations where these can occur (anywhere in the body), more data is needed to provide understanding of the safety and efficacy of hypofractionated radiotherapy for treatment of this disease. The hypothesis is that by using hypofractionated radiotherapy, highly conformal high dose radiation can be delivered to soft tissue sarcomas, while respecting established normal tissue constraints and that local control rates will be greater than historical rates reported with conventional fractionation. Eligible participants with biopsy proven soft tissue sarcoma will be on study for up to 60 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03972930
Study type	Interventional
Source	University of Wisconsin, Madison
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 11, 2019
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02910895` - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)	N/A
Recruiting	`NCT05621668` - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma	Phase 1
Active, not recruiting	`NCT04032964` - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS	Phase 1
Active, not recruiting	`NCT04577014` - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Completed	`NCT01650077` - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Terminated	`NCT02890368` - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT02204111` - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn	`NCT01663090` - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas	N/A
Completed	`NCT01259375` - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma	Phase 2
Completed	`NCT01440088` - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	Phase 3
Completed	`NCT01106872` - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas	Phase 1
Recruiting	`NCT00753727` - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma	Phase 1/Phase 2
Terminated	`NCT00755261` - Phase II Study of Doxorubicin and Avastin® in Sarcoma.	Phase 2
Completed	`NCT00611078` - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study	N/A
Completed	`NCT00580320` - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma	Phase 1
Completed	`NCT03452644` - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting	`NCT05539677` - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3